Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Qin Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2210-8197. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 4 papers · 2022: none · 2023: 3 papers

Papers 9

  1. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11427-022-2146-5↗
  2. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic … Co-author DOI 10.1007/s13402-023-00824-7↗
  3. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  4. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Last author DOI 10.1038/s41389-021-00311-4↗
  5. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  6. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Co-author DOI 10.7150/ijbs.49243↗
  7. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  8. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  9. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Co-author DOI 10.1158/1078-0432.ccr-18-2297↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhigang Zhang · 9 shared papers, 2019–2023 · strength 1.04
  2. Shu‐Heng Jiang · 9 shared papers, 2019–2023 · strength 1.04
  3. Yongwei Sun · 7 shared papers, 2019–2023 · strength 0.76
  4. Li-Peng Hu · 7 shared papers, 2019–2023 · strength 0.70
  5. Xu Wang · 5 shared papers, 2021–2023 · strength 0.62
  6. Qing Li · 5 shared papers, 2019–2023 · strength 0.52
  7. Dejun Liu · 3 shared papers, 2021–2023 · strength 0.36
  8. Xiaomei Yang · 3 shared papers, 2019–2023 · strength 0.35
  9. Minwei Yang · 3 shared papers, 2021–2023 · strength 0.34
  10. Rongkun Li · 3 shared papers, 2019–2023 · strength 0.34
  11. Shan Zhang · 2 shared papers, 2023 · strength 0.34
  12. Gary Guishan Xiao · 3 shared papers, 2019–2023 · strength 0.32
  13. Xueli Zhang · 3 shared papers, 2019–2021 · strength 0.27
  14. Rong Hua · 2 shared papers, 2019–2023 · strength 0.23
  15. Xin Xing · 2 shared papers, 2021 · strength 0.22
  16. Kaixia Zhou · 2 shared papers, 2021 · strength 0.20
  17. Linli Yao · 2 shared papers, 2021 · strength 0.20
  18. Yongsheng Jiang · 2 shared papers, 2019–2021 · strength 0.18
  19. Hong‐Fei Yao · 1 shared paper, 2023 · strength 0.18
  20. Hui Nie · 2 shared papers, 2019–2021 · strength 0.17
  21. Jian‐Yu Yang · 2 shared papers, 2019–2021 · strength 0.17
  22. Junfeng Zhang · 1 shared paper, 2023 · strength 0.16
  23. Dongxue Li · 1 shared paper, 2023 · strength 0.14
  24. Lili Zhu · 1 shared paper, 2021 · strength 0.11
  25. Yifan Zhang · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.